U.S. markets closed
  • S&P Futures

    4,514.00
    +2.75 (+0.06%)
     
  • Dow Futures

    35,350.00
    +27.00 (+0.08%)
     
  • Nasdaq Futures

    15,400.50
    +2.00 (+0.01%)
     
  • Russell 2000 Futures

    2,274.60
    +1.80 (+0.08%)
     
  • Crude Oil

    83.14
    +0.18 (+0.22%)
     
  • Gold

    1,768.60
    -1.90 (-0.11%)
     
  • Silver

    23.65
    -0.24 (-1.00%)
     
  • EUR/USD

    1.1633
    -0.0004 (-0.03%)
     
  • 10-Yr Bond

    1.6350
    +0.0510 (+3.22%)
     
  • Vix

    15.70
    -0.61 (-3.74%)
     
  • GBP/USD

    1.3789
    -0.0004 (-0.03%)
     
  • USD/JPY

    114.6470
    +0.2870 (+0.25%)
     
  • BTC-USD

    64,142.00
    +1,881.59 (+3.02%)
     
  • CMC Crypto 200

    1,486.50
    +23.14 (+1.58%)
     
  • FTSE 100

    7,217.53
    +13.70 (+0.19%)
     
  • Nikkei 225

    29,425.46
    +209.94 (+0.72%)
     

Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Affimed NV (NASDAQ: AFMD) has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research.

  • The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity.

  • The preclinical data published supported the Investigational New Drug (IND) application for the ongoing Phase 1 study of AFM13, precomplexed with cytokine-preactivated cbNK cells followed by AFM13 monotherapy in patients with CD30-positive malignancies.

  • Results as of March demonstrated an objective response rate of 100% (overall response rate=4/4; partial response=2/4; complete response=2/4) among the first patients enrolled who were all heavily pretreated.

  • There were no observed events of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.

  • Price Action: AFMD shares are trading 0.79% lower at $8.79 during the premarket session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.